- About the College
- Departments & Offices
- Veterinary Hospitals
Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease - EPIC
This study is closed (8/29/2012)
Purpose of the study:
The purpose of this study is to determine whether chronic oral administration of pimobendan in dogs with evidence of increased heart size secondary to preclinical myxomatous mitral valve disease, can delay the onset of signs of congestive heart failure.
Currently there is no cardiac drug licensed for the treatment of preclinical myxomatous mitral valve disease. Pimobendan has been proven to be safe and to reduce mortality as well as morbidity associated with congestive heart failure (CHF) due to myxomatous mitral valve disease. The combination of preload and afterload reduction in combination with inotropic support may result in a reduction in cardiac size and filling pressures in dogs with significant remodelling secondary to myxomatous mitral valve disease. These effects are considered to be cardioprotective and therefore, in dogs with preclinical myxomatous mitral valve disease, would be anticipated to delay the onset of pulmonary oedema and clinical signs.
To qualify for enrollment in this study, dogs must have:
- A moderate to high intensity systolic heart murmur with maximal intensity over the mitral area (≥ grade 3/6[a1] ).
- Animals must be at least six years of age.
- Animals must have a body weight ≥ 4.1 and ≤ 15 kg (≥ 9 and ≤ 33.1 lb)
- Radiographic evidence of cardiomegaly (VHS score > 10.5)
- Echocardiographic evidence of myxomatous mitral valve disease defined as characteristic valvular lesions of the mitral valve apparatus (leaflet thickening, valve prolapse, ruptured chordae tendineae)
- Presence of mitral regurgitation on the colour Doppler echocardiogram
Chronic treatment (> 14 days) for cardiovascular disease (enalapril, furosemide, etc.) within 30 days of Day 0, then the dog is not eligible for screening or enrolment.
This is a multi-center, placebo controlled, double blinded study. On Day 0 dogs will have physical examination, auscultation, radiographs, echocardiography, labwork, and blood pressure performed. Dogs meeting enrolment criteria will be randomized to either receive Pimobendan or Placebo, and will be reevaluated at day 35 ± 7, 4 Months, 8 Months, and every 4 months thereafter following entry and again at the time of clinical signs related to CHF.
Clients are responsible for paying for charges related to laboratory tests and other exams that may be requested beyond study design
The study will cover for approximately 80% or more of the client’s bill
- Adverse events confirmed to be directly related to the medication will be covered by the study
For more information on this study contact Nicole Stingle or Tamra Mathie at clinicaltrials [at] cvm [dot] osu [dot] edu